Analytical Data
-
基因名
MAGED4B
- Application
-
别名
MAGED4. KIAA1859. MAGED4A. MAGEE1. MAGED4B
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96JG8
-
表达区间
1-333aa
-
氨基酸序列
MIKDYKKIPIKRADMLKDVIREYDEHFPEIIERATYTLEKKFGIHLKEIDKEEHLYILVCTRDSSARLLGKTKDTPRLSLLLVILGVIFMNGNRASEAVLWEALRKMGLRPGVRHPFLGDLRKLITDDFVKQKNPELREETPLSMAPSWYLEYKKIPNSNPPEYEFLWGLRARHETSKMRVLRFIAQNQNRDPREWKAHFLEAVDDAFKTMDVDMAEEHARAQMRAQMNIGDEALIGRWSWDDIQVELLTWDEDGDFGDAWARIPFAFWARYHQYILNSNRANRRATWRAGVSSGTNGGASTSVLDGPSTSSTIRTRNAARAGASFFSWIQHR
-
分子量
65.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Human TIPARP Protein，His
Cat：PA2000-4968
Recombinant E.coli sodA Protein，His
Cat：PA1000-2237
Recombinant Human MAGEC1 Protein，GST
Cat：PA2000-9149
Protein Description
MAGED4B, or Melanoma Antigen Gene D4B, is a member of the MAGED gene family, which is known for its role in cancer biology and immune response. The study of MAGED4B has gained significant attention due to its potential implications in melanoma and other cancers, where it may contribute to tumorigenesis and immune evasion. Research indicates that MAGED4B could be a target for immunotherapy, as it is expressed in various tumor tissues but has limited expression in normal healthy cells, making it a promising candidate for cancer vaccine development. Moreover, the understanding of the regulation and function of MAGED4B in cancer cells is crucial for identifying its role in tumor progression and the development of resistance to therapies. Recent studies have explored the molecular mechanisms that control MAGED4B expression and its interaction with other oncogenic pathways. The ongoing research aims to elucidate the precise function of MAGED4B and to leverage its unique properties for the development of novel therapeutic strategies, including personalized medicine approaches, to improve outcomes for patients with malignant diseases.
